Melanoma Therapeutics Market to 2020

Description:

This report is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90–95% of all melanomas.

Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.

Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma's seviprotimut-L, Amgen's talimogene laherparepvec (T-VEC) and Roche and Genentech's cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca's selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.

Scope:

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for melanoma. The report covers and includes:
- An introduction to the melanoma indication, including disease symptoms, epidemiology, etiology, pathophysiology, staging, diagnosis and treatment.
- In-depth analysis of the current melanoma marketed products landscape including product profiles of the main drugs used in melanoma and heat maps that compare safety and efficacy parameters of the various drugs.
- Comprehensive analysis of the melanoma pipeline by phase of development, molecule type, molecular target and novelty. A comparative analysis of late-stage pipeline drugs that are likely to enter the market in the forecast period is also provided alongside heat maps.
- Additional in-depth analysis of melanoma clinical trials by size, duration, failure rates and primary and secondary endpoints.
- Multi-scenario forecast data for the market to 2020, taking into account how it will be affected by the introduction of new drugs and changes in disease epidemiology across the key developed markets, the US, Canada, the UK, France, Germany, Italy, Spain and Japan.
- Discussion of the licensing and co-development strategic consolidations landscape in melanoma, by Phase of development and molecule type, as well as an analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals.

Reasons to Purchase:

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:
- Gain a comprehensive understanding of the melanoma indication including segmentation of disease and treatment algorithms.
- Understand the current melanoma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved.
- Identify trends and developments within the melanoma pipeline including which molecule types and molecular targets are prominent.
- Consider market opportunities and potential risks by examining trends in melanoma clinical trial duration and size, as well as clinical trial failure rates, amongst clinical trial Phases and molecule types.
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the melanoma therapeutics market.

Contents:
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Types of Melanoma
2.3 Symptoms
2.3.1 Cutaneous Melanoma
2.3.2 Ocular Melanoma
2.3.3 Mucosal Melanomas
2.3.4 Melanomas of the Internal Organs and Soft Parts
2.3.5 Advanced Melanoma
2.4 Etiology and Risk Factors
2.4.1 Phenotypic Characteristics
2.4.2 Exposure to Ultraviolet Radiation
2.4.3 Personal or Family History of Melanoma
2.4.4 Xeroderma Pigmentosum
2.4.5 Parkinson's Disease
2.5 Pathophysiology
2.5.1 Cutaneous Melanoma
2.5.2 Ocular Melanoma
2.5.3 Mucosal Melanoma
2.5.4 Underlying Molecular Pathways
2.6 Melanoma Staging
2.7 Diagnosis
2.7.1 Cutaneous Melanoma
2.7.2 Ocular Melanoma
2.7.3 Mucosal Melanoma
2.8 Epidemiology
2.8.1 Cutaneous Melanoma
2.8.2 Ocular Melanoma
2.8.3 Mucosal Melanoma
2.9 Treatment Options
2.9.1 Surgery
2.9.2 Radiation Therapy
2.9.3 Pharmacotherapy
2.10 Treatment Algorithms
2.10.1 Cutaneous Melanoma
2.10.2 Ocular Melanoma
2.10.3 Mucosal Melanoma
2.11 Treatment Segments
2.11.1 Adjuvant Therapy for CM (All Mutations)
2.11.2 Advanced Therapy for CM (All Mutations)
2.11.3 Advanced Therapy for CM (BRAF Mutated Patients Only)

3 Marketed Products
3.1 Overview
3.2 Adjuvant therapy
3.2.1 Immunotherapy
3.3 Therapy for Advanced (Unresectable or Metastatic) Melanoma
3.3.1 Chemotherapy
3.3.2 Immunotherapy
3.3.3 Targeted Therapies
3.4 Heat Maps for Marketed Products

4 Melanoma Pipeline
4.1 Overview
4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
4.3 Pipeline Distribution by Molecular Target
7.2.9 Japan
7.3 References
7.3.1 References for Heat Maps
7.4 Abbreviations
7.5 Research Methodology
7.5.1 Secondary Research
7.5.2 Marketed Product Profiles
7.5.3 Late-Stage Pipeline Candidates
7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
7.5.5 Product Competitiveness Framework
7.5.6 Pipeline Analysis
7.5.7 Forecasting Model
7.5.8 Deals Data Analysis
7.6 Contact Us
7.7 Disclaimer

1.1 List of Tables
Table 1: Characteristics of Types of Melanoma
Table 2: Staging of Cutaneous Melanoma
Table 3: Melanoma Clinical Trial Endpoint Definitions
Table 4: Melanoma Therapeutics Market, Global, Pipeline, Groups of Molecular Targets, 2014
Table 5: Breakdown of ‘Other’ Molecular Targets
Table 6: Breakdown of Molecular Target Combinations
Table 7: Melanoma Therapeutics, Global, All Pipeline Products, Discovery Phase, 2014
Table 8: Melanoma Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014
Table 9: Melanoma Therapeutics, Global, All Pipeline Products, IND/CTA-filed Phase, 2014
Table 10: Melanoma Therapeutics, Global, All Pipeline Products, Phase I, 2014
Table 11: Melanoma Therapeutics, Global, All Pipeline Products, Phase II, 2014
Table 12: Melanoma Therapeutics, Global, All Pipeline Products, Phase III, 2014
Table 13: Melanoma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2014
Table 14: Melanoma Therapeutics Market, Global, Market Forecast, 2013–2020
Table 15: Melanoma Therapeutics Market, US, Market Forecast, 2013–2020
Table 16: Melanoma Therapeutics Market, Canada, Market Forecast, 2013–2020
Table 17: Melanoma Therapeutics Market, UK, Market Forecast, 2013–2020
Table 18: Melanoma Therapeutics Market, France, Market Forecast, 2013–2020
Table 19: Melanoma Therapeutics Market, Germany, Market Forecast, 2013–2020
Table 20: Melanoma Therapeutics Market, Italy, Market Forecast, 2013–2020
Table 21: Melanoma Therapeutics Market, Spain, Market Forecast, 2013–2020
Table 22: Melanoma Therapeutics Market, Japan, Market Forecast, 2013–2020
Table 23: List of Abbreviations

1.2 List of Figures
Figure 1: Melanoma Therapeutics Market, Global, Heat Map for Adjuvant Marketed Products, 2014
Figure 2: Melanoma Therapeutics Market, Global, Heat Map for Advanced Marketed Products, 2014
Figure 3: Melanoma Therapeutics Market, Global, Heat Map for Advanced Marketed Products, 2014
(continued)
Figure 4: Melanoma Therapeutics Market, Global, Pipeline, 2014
Figure 5: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Biologics and Gene/Cell Therapies, 2014
Figure 6: Melanoma Therapeutics Market, Global, Pipeline, Repositioned Molecules by Original Indication, 2014
Figure 7: Melanoma Therapeutics Market, Global, Pipeline by Molecular Target, 2014
Figure 8: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Protein Kinase Molecular Targets by Phase of Development, 2014
Figure 9: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Antigens/Antigen Ligands Molecular Targets by Phase of Development, 2014
Figure 10: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Cytokine/Cytokine Receptor Molecular Targets by Phase of Development, 2014
Figure 11: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates by Phase of Development and Overall Clinical Trial Attrition Rate, 2006–2013 (%)
Figure 12: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates (Phases I, II and III) and Clinical Trial Attrition Rate by Molecule Type (%), 2006–2013
Figure 13: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates (Phases I, II and III) and Clinical
Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3030121/](http://www.researchandmarkets.com/reports/3030121/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Melanoma Therapeutics Market to 2020
Web Address: http://www.researchandmarkets.com/reports/3030121/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 4995</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 14985</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 9990</td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  Mrs  Dr  Miss  Ms  Prof
First Name:  
Last Name:  
Email Address: *
Job Title:  
Organisation:  
Address:  
City:  
Postal / Zip Code:  
Country:  
Phone Number:  
Fax Number:  

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World